• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Rheumatoid arthritis (RA) - Articles and news items

Sanofi and Regeneron receive CHMP positive opinion for rheumatoid arthritis treatment

Industry news / 28 April 2017 / Niamh Marriott, Junior Editor

The European Medicine Agency’s CHMP has adopted a positive opinion for the marketing authorisation of Sanofi and Regeneron Pharmaceuticals’ Kevzara…

Sandoz proposed biosimilars recommended for EU approval

Industry news / 25 April 2017 / Niamh Marriott, Junior Editor

CHMP has adopted positive opinions, separately recommending the approval of both Sandoz’s biosimilar rituximab and biosimilar etanercept in Europe…

2017 Pipelines: Drugs to watch

Blog, Z Homepage promo / 12 April 2017 / Alexandra Kibble, Senior Editor, Clarivate Analytics Cortellis

The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021…

EC approves Eli Lilly’s rheumatoid arthritis drug

Industry news / 16 February 2017 / Niamh Marriott, Digital Editor

The European Commission has granted marketing authorisation for Eli Lilly and Incyte’s baricitinib (Olumiant) for the treatment of moderate to severe active rheumatoid arthritis (RA), in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with […]

FDA extends review period for Eli Lilly’s rheumatoid arthritis drug

Industry news / 16 January 2017 / Niamh Marriott, Digital Editor

Baricitinib is also being studied in phase 2 trials for atopic dermatitis and systemic lupus erythematosus, and a phase 3 trial for patients…

Janssen submits EU application for rheumatoid arthritis drug

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis…

FDA approves Novartis’ biosimilar to treat multiple inflammatory diseases

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis…

cimzia arthritis x-ray hands bones

Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab

Industry news / 1 August 2016 / Sanofi / Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis…

FDA committee recommends approval of Sandoz’s biosimilar etanercept

Industry news / 14 July 2016 / Victoria White, Digital Content Producer

The Arthritis Advisory Committee voted unanimously in support of biosimilar etanercept for all five indications of the reference product…

NICE recommends certolizumab pegol in draft guidance

Industry news / 12 July 2016 / Victoria White, Digital Content Producer

Certolizumab pegol is recommended as an option for people with severe rheumatoid arthritis when other drugs haven’t worked or aren’t suitable…

Rheumatoid arthritis testing market to hit $399.5m by 2022

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

The rheumatoid arthritis testing market is forecast to rise from $338.5 million in 2015 to $399.5 million by 2022, according to GlobalData…

New data for baricitinib in rheumatoid arthritis presented at EULAR

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

Findings from the RA-BEYOND study demonstrate that baricitinib was superior to placebo at inhibiting progressive radiographic joint damage…